Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Mieke Ptaszynski"'
Autor:
Rami Komrokji, Hagop Kantarjian, Alan List, Zach Bohannan, Monica Cabrero Calvo, Mieke Ptaszynski, Grant Hogeland, Lara Maloney, Selena Rush, LouAnn Cable, Shannon L. Winski, Jeffrey Lancet, Elias Jabbour, Hanna J. Khoury, Guillermo Garcia-Manero
Figure S1. EPO and plasma chemokine expression following treatment with ARRY-614 at 1200 mg QD. Figure S2. Comparison of EPO in IWG2006 Responders and Non-Responders.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2749539b558aaeff86cdad94db594726
https://doi.org/10.1158/1078-0432.22461647.v1
https://doi.org/10.1158/1078-0432.22461647.v1
Autor:
Rami Komrokji, Hagop Kantarjian, Alan List, Zach Bohannan, Monica Cabrero Calvo, Mieke Ptaszynski, Grant Hogeland, Lara Maloney, Selena Rush, LouAnn Cable, Shannon L. Winski, Jeffrey Lancet, Elias Jabbour, Hanna J. Khoury, Guillermo Garcia-Manero
Purpose: Data suggest that activity of p38 MAPK and Tie2 kinases is dysregulated in myelodysplastic syndromes (MDS) and may be targets for novel therapies. A phase I study of ARRY-614, an oral dual inhibitor of p38 MAPK and Tie2, was conducted in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60d5f52fbd9e9d5a154f342f65d7d7a
https://doi.org/10.1158/1078-0432.c.6524846.v1
https://doi.org/10.1158/1078-0432.c.6524846.v1
Autor:
Rami Komrokji, Hagop Kantarjian, Alan List, Zach Bohannan, Monica Cabrero Calvo, Mieke Ptaszynski, Grant Hogeland, Lara Maloney, Selena Rush, LouAnn Cable, Shannon L. Winski, Jeffrey Lancet, Elias Jabbour, Hanna J. Khoury, Guillermo Garcia-Manero
Supplemental Table 2. Dose escalation PK parameters for ARRY-614
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98ae6d70f6b3f0940c1ec0aca3daa6cd
https://doi.org/10.1158/1078-0432.22461650
https://doi.org/10.1158/1078-0432.22461650
Autor:
Rami Komrokji, Hagop Kantarjian, Alan List, Zach Bohannan, Monica Cabrero Calvo, Mieke Ptaszynski, Grant Hogeland, Lara Maloney, Selena Rush, LouAnn Cable, Shannon L. Winski, Jeffrey Lancet, Elias Jabbour, Hanna J. Khoury, Guillermo Garcia-Manero
Supplemental Table 1. Treatment-emergent AEs (safety population)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::071bb0c0accd07d3d7702ce3c4eeb15c
https://doi.org/10.1158/1078-0432.22461653
https://doi.org/10.1158/1078-0432.22461653
Autor:
Kevin Kalinsky, Joanne E. Mortimer, José Agustín Quincoces Suárez, Julie R. Nangia, Matt Suster, Mieke Ptaszynski, Pavani Chalasani, Vandana G. Abramson
Publikováno v:
Cancer Research. 81:PS12-20
Background: ZN-c5 is an orally bioavailable selective estrogen receptor degrader (SERD) that binds potently to the estrogen receptors alpha and beta. It shows improved activity over fulvestrant in human tumor xenograft models and activity in tumor mo
Autor:
Karim A. Benhadji, Ian E. Krop, Miguel Martin, Carlos L. Arteaga, Senthil Damodaran, Yaohua He, Nicholas C. Turner, Aditya Bardia, Mieke Ptaszynski
Publikováno v:
Cancer Research. 80:OT2-07
Background: FGFR1 gene amplifications occur in ~15% of invasive breast cancers (BCs) andhave been shown to be associated with endocrine therapy resistance, whereas FGFR2 amplifications occur in ~2% of invasive BCs (4% of triple-negative BCs [TNBCs]).
Autor:
Jonathan L. Kaufman, Robert Z. Orlowski, Selena A Rush, Jeffrey A. Zonder, Walker Duncan H, Adam D. Cohen, Jatin J. Shah, Brandi Hilder, Kevin Litwiler, Mieke Ptaszynski, Brian J. Tunquist, William I. Bensinger, Sagar Lonial
Publikováno v:
Cancer. 123:4617-4630
BACKGROUND Filanesib (ARRY-520) is a highly selective inhibitor of kinesin spindle protein, which has demonstrated preclinical antimyeloma activity. METHODS This open-label Phase 1/2 study determined the maximum tolerated dose of Filanesib administer
Autor:
Steven Michael Burt, Jonathan L. Kaufman, Joseph W. Fay, Kenneth Lau, Jeffrey A. Zonder, Ajai Chari, Brian J. Tunquist, Myo Htut, Selena A Rush, Andrzej Jakubowiak, Joan Levy, Mieke Ptaszynski, Walker Duncan H, Brandi Hilder
Publikováno v:
Cancer. 122:3327-3335
BACKGROUND Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy with bortezomib was the rationale for the current phase 1 study. METHOD
Autor:
Selena A Rush, Priscila H. Goncalves, Jennifer Schreiber, Judith A. Carter, Kevin Litwiler, Edward A. Sausville, Dale Roseberry, Heidi Simmons, Lindsay Casetta, Patricia LoRusso, Mieke Ptaszynski
Publikováno v:
Investigational New Drugs. 33:440-449
Purpose Filanesib (ARRY-520) is a highly selective, targeted inhibitor of kinesin spindle protein (KSP) inhibitor that induces mitotic arrest and subsequent tumor cell death. This first-in-human Phase 1 study evaluated dose-limiting toxicities (DLTs)
Autor:
Ajai, Chari, Myo, Htut, Jeffrey A, Zonder, Joseph W, Fay, Andrzej J, Jakubowiak, Joan B, Levy, Kenneth, Lau, Steven M, Burt, Brian J, Tunquist, Brandi W, Hilder, Selena A, Rush, Duncan H, Walker, Mieke, Ptaszynski, Jonathan L, Kaufman
Publikováno v:
Cancer. 122(21)
BACKGROUND: Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy with bortezomib was the rationale for the current phase 1 study. METHO